학술논문
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Banerjee, Susana ; Moore, Kathleen N; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung-Gie; Oaknin, Ana; Friedlander, Michael; Lisyanskaya, Alla; Floquet, Anne; Leary, Alexandra; Sonke, Gabe S; Gourley, Charlie; Oza, Amit; González-Martín, Antonio; Aghajanian, Carol; Bradley, William H; Holmes, Eileen; Lowe, Elizabeth S; DiSilvestro, Paul
Source
In The Lancet Oncology December 2021 22(12):1721-1731
Subject
Language
ISSN
1470-2045